(NYSEMKT: PTHS) Pelthos Therapeutics's forecast annual revenue growth rate of 44.22% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.4%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.69%.
Pelthos Therapeutics's revenue in 2026 is $43,304,000.On average, 9 Wall Street analysts forecast PTHS's revenue for 2026 to be $249,229,503, with the lowest PTHS revenue forecast at $211,718,164, and the highest PTHS revenue forecast at $319,661,848. On average, 9 Wall Street analysts forecast PTHS's revenue for 2027 to be $433,650,684, with the lowest PTHS revenue forecast at $380,434,965, and the highest PTHS revenue forecast at $482,387,094.
In 2027, PTHS is forecast to generate $473,198,768 in revenue, with the lowest revenue forecast at $399,845,302 and the highest revenue forecast at $630,280,851.